

Indication	Probe name	Location
<b>Myeloid Disorders</b>		
<b>Myelodysplastic Syndrome (MDS)/Myeloproliferative Neoplasms</b>		
Monsomy 5 / 5q-	D5S721/EGR1	5p15.2 / 5q31
Monsomy 7 / 7q-	D7Z1/D7S486	7cen, 7q31
Trisomy 8	CEP 8	8cen
Monsomy 20 / 20q-	D20S108	20q12
t(9;22)(q34;q11.2)	BCR/ABL1	22q11.2 / 9q34
4q12 (CHIC2 deletion)	FIPIL1/CHIC2/PDGFRA	4q12
5q33	PDGFRB	5q33
11q23 rearrangements	MLL	11q23
13q-	D13S319	13q14.3

<b>Acute Myeloid Leukemia (AML)</b>		
Monsomy 5 / 5q-	D5S721/EGR1	5p15.2 / 5q31
Monsomy 7 / 7q-	D7Z1/D7S486	7cen, 7q31
Trisomy 8	CEP8	8cen
Monsomy 20 / 20q-	D20S108	20q12
t(9;22)(q34;q11.2)	BCR/ABL1	22q11.2 / 9q34
11q23 rearrangements	MLL	11q23
inv (16)(p13q22) / t(16;16)	CBFB	16q22
t(8;21)(q22;q22)	RUNX1T1/RUNX1 (ETO/AML1)	8q22, 21q22
t(15;17)(q22;q21)	PML/RARA	15q22, 17q12-21

<b>Chronic Myelogenous Leukemia (CML)</b>		
t(9;22)(q34;q11.2)	BCR/ABL1	22q11.2 / 9q34
del(9q)	ASS1	
Trisomy 8	CEP8	8cen

<b>Pediatric Acute Myelogenous Leukemia</b>		

<b>Lymphoid Disorders</b>		
<b>Acute Lymphoblastic Leukemia (ALL)</b>		

t(9;22)(q34;q11.2)	BCR/ABL1	22q11.2 / 9q34
11q23 rearrangements	MLL	11q23
t(12;21)(p13;q22)	ETV6/RUNX1 (TEL/AML1)	12p13, 21q22
<b>T-cell Acute Lymphoblastic Leukemia</b>		
14q11.2	TRA (TCRA/TCRD)	14q11
<b>Chronic Lymphocytic Leukemia (CLL)</b>		
11q	ATM	11q22.3
CEP12	CEP12	12q11.1-q11
13q-	D13S319	13q14.3
17p	TP53 (p53)	17p13.1
14q	IGH	14q32.33
6q23	MYB	6q23
<b>Pediatric pre-B-cell Acute Lymphoblastic Leukemia</b>		
Trisomy 4, 10, 17	CEP 4, CEP10, CEP 17	
t(9;22)(q34;q11.2)	BCR/ABL1	22q11.2 / 9q34
11q23 rearrangements	MLL	11q23
t(12;21)(p13;q22)	ETV6/RUNX1 (TEL/AML1)	12p13, 21q22
t(1;19)	PBX1/E2A	1q23, 19p13.3
<b>Lymphomas</b>		
<b>Anaplastic Large Cell Lymphoma</b>		
t(2;5)	ALK	2p23
<b>Burkitt's Lymphoma</b>		
t(8;14)	IGH/MYC	8q24
<b>Follicular/Diffuse Large B cell Lymphoma</b>		
t(14;18)	IGH/BCL2	14q32, 18q21
8	MYC (cMYC)	8q24
<b>Non-Burkitt's/Non-Hodgkin's Lymphoma</b>		
3q27	BCL6	3q27
<b>MALT Lymphoma</b>		
t(11;18)	API2/MALT1	11q21, 18q21
18q21	MALT1	18q21
<b>Mantle Cell Lymphoma</b>		
t(11;14)	IGH/CCND1	11q13, 14q32

<b>Multiple Myeloma (MM)</b>		
Trisomy 5	D5S721/EGR1	5p15.2, 5q31
Trisomy 7	D7Z1/D7S486	7cen, 7q31
13q-	D13S319	13q14.3, 13q34
17p	TP53 (p53)	17p13.1
t(4;14)	FGFR3/IGH	14q32;4p16.3
t(11;14)	IGH/CCND1	11q13;14q32
t(14;16)	IGH/MAF	14q32;16q23
14q	IGH	14q32.33
<b>Bone Marrow Transplant (sex mismatched)</b>		
XX/XY	CEP X / CEPY	Xcen, Yq12
Other previously established abnormalities	Inquire for probe availability	
<b>Solid Tumors</b>		
<b>Sarcomas</b>		
Myxoid liposarcoma	DDIT3 (CHOP)	12q13.1-q13.2
Synovial sarcoma	SS18 (SYT)	18q11.2
Ewing sarcoma	EWSR1	22q12
<b>Glioma/Astro***</b>		
1 / 19 (glioma)		
<b>Neuroblastoma</b>		
2	N-MYC	2p24.1

7	EGFR	7p12
<b>Bladder Cancer</b>		
Urovysion® includes:		
3	CEP 3	3p11.1-q11.1
7	CEP 7	3p11.1-q11.1
9p21	CDKN2A (p16)	9p21
17	CEP 17	17p11.1-q11.1

|

|

|

|

IGH

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_